Damon Kimes, MD
Pain Medicine · Roswell, GANPI 1134282114
Payments from drug & device makers
Across 158 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Virtus Pharmaceuticals LLC$439
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$437
- Indivior Inc.$284
- USWM, LLC$266
- Forte Bio-pharma LLC$193
- MDD US Operations, LLC$183
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Virtus Pharmaceuticals LLC | 30 | $439 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $437 |
| Indivior Inc. | 11 | $284 |
| USWM, LLC | 11 | $266 |
| Forte Bio-pharma LLC | 4 | $193 |
| MDD US Operations, LLC | 9 | $183 |
| Medtronic | 1 | $109 |
| Amgen | 6 | $109 |
| Merz North America, Inc. | 2 | $108 |
| Collegium Pharmaceutical, Inc. | 6 | $100 |
| Abbott | 4 | $80 |
| Daiichi Sankyo Inc. | 5 | $79 |
| Fidia Pharma USA Inc. | 4 | $73 |
| Scilex Pharmaceuticals Inc. | 2 | $70 |
| Sentynl Therapeutics, Inc. | 5 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Lilly USA, LLC | 3 | $53 |
| Lundbeck LLC | 2 | $44 |
| Pfizer | 3 | $36 |
| Biodelivery Sciences International, Inc. | 2 | $31 |
| Braeburn Inc. | 1 | $27 |
| Almatica Pharma LLC | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| Zyla Life Sciences, Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Valinor Pharma, LLC | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Novartis | 1 | $15 |
| Protega Pharmaceutials Inc | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Alkermes, Inc. | 1 | $13 |
| Kaleo, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolate$391
- Nalocet$130
- SYNCHROMEDII$109
How this compares
$3,083 in reported general payments places this provider in the 50th percentile of 203 pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 183 | $62,834 |
| RelistorMethylnaltrexone Bromide | 23 | $52,723 |
| OxycontinOxycodone Hcl | 26 | $34,315 |
| MovantikNaloxegol Oxalate | 78 | $31,504 |
| Aimovig AutoinjectorErenumab-Aooe | 36 | $26,028 |
| Xtampza ErOxycodone Myristate | 56 | $25,577 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 842 | $24,393 |
| Oxycodone Hcl | 684 | $15,164 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 99 | $13,531 |
| Diclofenac Sodium | 182 | $7,037 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 252 | $6,286 |
| ButransBuprenorphine | 12 | $6,201 |
| Lidocaine | 68 | $6,146 |
| Morphine Sulfate ErMorphine Sulfate | 159 | $4,909 |
| Pregabalin | 204 | $3,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl | $18 | $77,580318 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $437 | $52,72323 claims |
| Redhill Biopharma Inc.Movantik | $14 | $31,50478 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $100 | $25,57756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 203 pain medicine providers in Georgia.
Other pain medicine in Roswell
- Joseph KundukulamRoswell$10K
- Alan HarbenRoswell$6K
- Arnold WeilMarietta$286K
- Jeffrey GrossmanAtlanta$189K
- Vicente GalanStockbridge$95K
- Rutvij ShahColumbus$86K
- Anthony GrassoMarietta$79K
- Subodh AgrawalAthens$76K
- Maged HamzaGainesville$50K
- Siddardth UmapathyFort Eisenhower$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.